Novel anticancer Pd-II complexes: The effect of the conjugation of transferrin binding peptide and the nature of halogen coordinated on antitumor activity

Autor(es)

Teles, C. M. ^[1] ; Lammoglia, L. C. ^[2] ; Juliano, M. A. ^[3] ; Ruiz, A. L. T. G. ^[2] ; Candido, T. Z. ^[4] ; de Carvalho, J. E. ^[2] ; Lima, C. S. P. ^[4] ; Abbehausen, C. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Campinas UNICAMP, Inst Chem, POB 6154, BR-13083970 Campinas, SP - Brazil

^[2] Univ Estadual Campinas, UNICAMP, Fac Pharmaceut Sci, BR-13083871 Campinas, SP - Brazil

^[3] Univ Fed Sao Paulo, Escola Paulista Med, UNIFESP, BR-04063062 Sao Paulo, SP - Brazil

^[4] Univ Estadual Campinas, UNICAMP, Fac Med Sci, BR-13083970 Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Journal of Inorganic Biochemistry; v. 199, OCT 2019.
• Citações Web of Science: 4

Resumo

A series of Pd-II complexes with bis-(2-pyridylmethyl)glycine as a ligand of formula {[}PdX(bis-(2-pyridylmethyl) glycine)] where X = CI, Br, I were prepared and the effect of the halogen nature in the antitumor activity of eight tumorigenic and one non-tumorigenic cell line was evaluated. The chloride derivative was further functionalized with a transferrin receptor binding peptide, generating the first Pd-II based metallopeptide. Its antitumor activity was also evaluated. However, among all the complexes, the chloride and iodine parent compounds showed the lowest GI(50) values in the panel evaluated, and lowest GI(50) than cisplatin in several cell lines. In contrast, the bromine derivative showed higher values of GI(50) than chloride and iodine (around 30 - 50 mu M). The same trend was observed for the bovine serum albumin binding constant with higher values for iodine, chlorine, and bromine in this order. In aqueous solution, the chloride is exchanged by water while the bromine and iodine are not. DNA was evaluated as a target and showed no significative interaction for all the compounds. The results suggest sulfur-rich proteins and not DNA as a target. This report represents the first Pd-II metallopeptide reported, its evaluation in solution and antitumor activity. This work opens the possibilities for further functionalization of Pd-II complexes and the importance of the halogen coordination in the design of novel metallodrugs. (AU)

• Processo FAPESP: 17/12719-0 - Combate à resitência bacteriana: complexos metálicos e a inibição de metalo-beta-lactamses
• Beneficiário: Camilla Abbehausen
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 18/13588-0 - EMU concedido no processo 2012/50191-4: espectrômetro de massas IMPACT II da Bruker
• Beneficiário: Maria Aparecida Juliano
• Modalidade de apoio: Auxílio à Pesquisa - Programa Equipamentos Multiusuários
• Processo FAPESP: 16/07729-4 - Complexos metálicos de ouro, paládio e prata no tratamento do carcinoma de células escamosas de pele
• Beneficiário: Tuany Zambroti Cândido
• Modalidade de apoio: Bolsas no Brasil - Doutorado